Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Sold Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $15,001 and $50,000 in Crinetics Pharmaceuticals stock on July 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Crinetics Pharmaceuticals Stock Performance

NASDAQ CRNX opened at $84.95 on Tuesday. The business’s 50-day moving average price is $79.85 and its 200 day moving average price is $52.46. Crinetics Pharmaceuticals, Inc. has a twelve month low of $30.25 and a twelve month high of $85.01. The company has a market capitalization of $9.01 billion, a PE ratio of -16.86 and a beta of 0.08.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.04. Crinetics Pharmaceuticals had a negative return on equity of 44.22% and a negative net margin of 1,189.88%.The company had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $14.84 million. During the same quarter in the previous year, the business earned ($1.23) EPS. The firm’s revenue was up 2336.9% on a year-over-year basis. Equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -4.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CRNX shares. Evercore downgraded shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Robert W. Baird lifted their price target on shares of Crinetics Pharmaceuticals from $62.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Piper Sandler downgraded Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, September 2nd. Finally, Jefferies Financial Group cut Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and lifted their target price for the company from $55.00 to $85.00 in a report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $81.00.

Insider Transactions at Crinetics Pharmaceuticals

In other news, Director Stephanie Okey sold 6,900 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total value of $246,123.00. Following the completion of the sale, the director owned 6,400 shares in the company, valued at approximately $228,288. This trade represents a 51.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Vivaldi sold 3,000 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the sale, the director owned 19,225 shares in the company, valued at approximately $769,000. The trade was a 13.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. HighTower Advisors LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 2nd quarter valued at $207,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Crinetics Pharmaceuticals in the second quarter valued at about $494,000. California State Teachers Retirement System raised its position in Crinetics Pharmaceuticals by 3,523.8% in the second quarter. California State Teachers Retirement System now owns 3,825,409 shares of the company’s stock valued at $143,147,000 after purchasing an additional 3,719,846 shares during the period. Nykredit A S acquired a new position in shares of Crinetics Pharmaceuticals during the second quarter worth about $93,000. Finally, Montanova Capital LLC boosted its position in shares of Crinetics Pharmaceuticals by 13.6% in the second quarter. Montanova Capital LLC now owns 1,186,279 shares of the company’s stock worth $44,391,000 after buying an additional 142,400 shares during the period. Hedge funds and other institutional investors own 98.51% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.